Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

About the trial

Sponsor

Boston Scientific Corporation

Tested

CRT-D with a Quadripolar LV lead (device), CRT-D with INGEVITY+ pace/sense lead (device)

Dates

Started 2025-10-22; completion 2029-11

Results posted

Not yet

This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT). 2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $46,016 in research payments for this study in 2025 (4 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.